Cargando…
Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Daka...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471902/ https://www.ncbi.nlm.nih.gov/pubmed/28615016 http://dx.doi.org/10.1186/s12936-017-1897-6 |
_version_ | 1783244041032302592 |
---|---|
author | Mbaye, Aminata Gaye, Amy Dieye, Baba Ndiaye, Yaye D. Bei, Amy K. Affara, Muna Deme, Awa B. Yade, Mamadou S. Diongue, Khadim Ndiaye, Ibrahima M. Ndiaye, Tolla Sy, Mouhamed Sy, Ngayo Koita, Ousmane Krogstad, Donald J. Volkman, Sarah Nwakanma, Davis Ndiaye, Daouda |
author_facet | Mbaye, Aminata Gaye, Amy Dieye, Baba Ndiaye, Yaye D. Bei, Amy K. Affara, Muna Deme, Awa B. Yade, Mamadou S. Diongue, Khadim Ndiaye, Ibrahima M. Ndiaye, Tolla Sy, Mouhamed Sy, Ngayo Koita, Ousmane Krogstad, Donald J. Volkman, Sarah Nwakanma, Davis Ndiaye, Daouda |
author_sort | Mbaye, Aminata |
collection | PubMed |
description | BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Dakar region in 1988 with nearly 7% population prevalence, reaching 47% by 1990. It is in this context that sulfadoxine–pyrimethamine temporarily replaced chloroquine as first line treatment in 2003, pending the introduction of artemisinin-based combination therapy in 2006. The purpose of this study is to assess the ex vivo sensitivity to different anti-malarial drugs of the P. falciparum population from Pikine. METHODS: Fifty-four samples were collected from patients with non-complicated malaria and aged between 2 and 20 years in the Deggo health centre in Pikine in 2014. An assay in which parasites are stained with 4′, 6-di-amidino-2-phenylindole (DAPI), was used to study the ex vivo sensitivity of isolates to chloroquine, amodiaquine, piperaquine, pyrimethamine, and dihydroartemisinin. High resolution melting was used for genotyping of pfdhps, pfdhfr, pfmdr1, and pfcrt genes. RESULTS: The mean IC(50)s of chloroquine, amodiaquine, piperaquine, dihydroartemisinin, and pyrimethamine were, respectively, 39.44, 54.02, 15.28, 2.23, and 64.70 nM. Resistance mutations in pfdhfr gene, in codon 437 of pfdhps gene, and an absence of mutation at position 540 of pfdhps were observed. Mutations in codons K76T of pfcrt and N86Y of pfmdr1 were observed at 51 and 11% population prevalence, respectively. A relationship was found between the K76T and N86Y mutations and ex vivo resistance to chloroquine. CONCLUSION: An increase in sensitivity of isolates to chloroquine was observed. A high sensitivity to dihydroartemisinin was observed; whereas, a decrease in sensitivity to pyrimethamine was observed in the parasite population from Pikine. |
format | Online Article Text |
id | pubmed-5471902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54719022017-06-19 Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal Mbaye, Aminata Gaye, Amy Dieye, Baba Ndiaye, Yaye D. Bei, Amy K. Affara, Muna Deme, Awa B. Yade, Mamadou S. Diongue, Khadim Ndiaye, Ibrahima M. Ndiaye, Tolla Sy, Mouhamed Sy, Ngayo Koita, Ousmane Krogstad, Donald J. Volkman, Sarah Nwakanma, Davis Ndiaye, Daouda Malar J Research BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Dakar region in 1988 with nearly 7% population prevalence, reaching 47% by 1990. It is in this context that sulfadoxine–pyrimethamine temporarily replaced chloroquine as first line treatment in 2003, pending the introduction of artemisinin-based combination therapy in 2006. The purpose of this study is to assess the ex vivo sensitivity to different anti-malarial drugs of the P. falciparum population from Pikine. METHODS: Fifty-four samples were collected from patients with non-complicated malaria and aged between 2 and 20 years in the Deggo health centre in Pikine in 2014. An assay in which parasites are stained with 4′, 6-di-amidino-2-phenylindole (DAPI), was used to study the ex vivo sensitivity of isolates to chloroquine, amodiaquine, piperaquine, pyrimethamine, and dihydroartemisinin. High resolution melting was used for genotyping of pfdhps, pfdhfr, pfmdr1, and pfcrt genes. RESULTS: The mean IC(50)s of chloroquine, amodiaquine, piperaquine, dihydroartemisinin, and pyrimethamine were, respectively, 39.44, 54.02, 15.28, 2.23, and 64.70 nM. Resistance mutations in pfdhfr gene, in codon 437 of pfdhps gene, and an absence of mutation at position 540 of pfdhps were observed. Mutations in codons K76T of pfcrt and N86Y of pfmdr1 were observed at 51 and 11% population prevalence, respectively. A relationship was found between the K76T and N86Y mutations and ex vivo resistance to chloroquine. CONCLUSION: An increase in sensitivity of isolates to chloroquine was observed. A high sensitivity to dihydroartemisinin was observed; whereas, a decrease in sensitivity to pyrimethamine was observed in the parasite population from Pikine. BioMed Central 2017-06-14 /pmc/articles/PMC5471902/ /pubmed/28615016 http://dx.doi.org/10.1186/s12936-017-1897-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Mbaye, Aminata Gaye, Amy Dieye, Baba Ndiaye, Yaye D. Bei, Amy K. Affara, Muna Deme, Awa B. Yade, Mamadou S. Diongue, Khadim Ndiaye, Ibrahima M. Ndiaye, Tolla Sy, Mouhamed Sy, Ngayo Koita, Ousmane Krogstad, Donald J. Volkman, Sarah Nwakanma, Davis Ndiaye, Daouda Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title | Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title_full | Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title_fullStr | Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title_full_unstemmed | Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title_short | Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal |
title_sort | ex vivo susceptibility and genotyping of plasmodium falciparum isolates from pikine, senegal |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471902/ https://www.ncbi.nlm.nih.gov/pubmed/28615016 http://dx.doi.org/10.1186/s12936-017-1897-6 |
work_keys_str_mv | AT mbayeaminata exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT gayeamy exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT dieyebaba exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT ndiayeyayed exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT beiamyk exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT affaramuna exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT demeawab exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT yademamadous exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT dionguekhadim exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT ndiayeibrahimam exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT ndiayetolla exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT symouhamed exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT syngayo exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT koitaousmane exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT krogstaddonaldj exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT volkmansarah exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT nwakanmadavis exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal AT ndiayedaouda exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal |